Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
DURHAM, N.C., Feb. 16, 2016 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that detailed results from the Company’s Phase 3 SUPPRESS trial of brincidofovir in patients undergoing hematopoietic cell transplantation (HCT), will be presented at the BMT Tandem Meetings in Honolulu, Hawaii. The presentation will be held on Saturday, February 20, 2016 at 4:00 p.m. HST (9:00 p.m. EST) at the Hawaii Convention Center in Honolulu, Hawaii. Presentation slides will be posted to the Chimerix website following the conclusion of the presentation.
Chimerix’s management team will host a live conference call and webcast at 8:00 a.m. EST on Monday, February 22, 2016 to discuss the SUPPRESS trial results as well as provide an update on the brincidofovir clinical program. To access the live conference call, please dial 877-354-4056 (domestic) or 678-809-1043 (international) at least five minutes prior to the start time and refer to conference ID 52881232.
A live webcast of the call and accompanying slides will also be available on the Investors’ section of the Company’s website, www.chimerix.com and an archived webcast will be available on the Chimerix website approximately two hours after the event.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals in areas of high unmet medical need. Chimerix's proprietary lipid conjugate technology has produced brincidofovir (CMX001), a clinical-stage nucleotide analog, CMX157 which was licensed to ContraVir Pharmaceuticals in 2014, and early clinical candidates including CMX669. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT: Investor Relations: [email protected] or Jesse Baumgartner Stern Investor Relations [email protected] 212-362-1200 Media: Becky Vonsiatsky W2O Group [email protected] 413-478-2003
